摘要
表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFRTKIs)靶向治疗如今成为EGFR基因突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的主导治疗方式,但随着用药时间的延长,大部分患者出现靶向药物的耐药。肿瘤微环境是肿瘤细胞赖以生存和发展的内环境,微环境中调节T(regulatory T,Treg)细胞、树突状细胞、巨噬细胞、成纤维细胞等免疫细胞介导的免疫反应以及程序性死亡受体1(programed cell death protein 1,PD-1)及其配体PD-1L/PD-2L可能参与EGFR-TKIs的耐药形成,现本综述将阐述肿瘤微环境中免疫细胞对EGFR-TKIs靶向治疗疗效相互影响的可能机制,以期寻求新的靶点,进一步提高EGFR-TKIs的抗肿瘤疗效和延长有效时间。
In recent years, targeted therapy of epidermal growth factor receptor-tyrosine kinase inhibitor（EGFRTKIs） is the leading treatment modality for patients with advanced non-small cell lung cancer（NSCLC） and EGFR gene mutation. However, with the prolongation of the medication time, most of the patients appeared drug resistance. Tumor microenvironment is the internal environment for the survival and development of tumor cells. The immune response which mediated by immune cells, like regulatory T（Treg）, dendritic cells, macrophages, fibroblasts, etc. And the programmed cell death receptor 1（PD-1） with its ligand PD-1 L/PD-2 L may participate in the drug resistance of EGFR-TKIs. This review will elaborate the possible mechanism of the interaction of immune cells on EGFR-TKIs in the tumor microenvironment, in order to seek new targets, and further improve the anti-tumor efficacy and prolong the effective time of EGFR-TKIs.
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2017年第11期775-780,共6页
Chinese Journal of Lung Cancer
基金
省级计划自然科学基金面上项目(No.20161BAB205265)资助~~
关键词
肿瘤微环境
肺肿瘤
靶向治疗
免疫细胞
EGFR-TKIS
PD-1
Tumor microenvironment
Lung neoplasms
Targeted therapy
Immune cells
EGFR-TKIs
Programed cell death protein 1
